Jang-Won Son

Jang-Won Son

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
MKMinkwan Kim
Minkwan Kim
JNJong-Ho Nam
Jong-Ho Nam
JSJang-Won Son
Jang-Won Son
SKSun Oh Kim
Sun Oh Kim
NSNak-Hoon Son
Nak-Hoon Son
IJIn Hyun Jung
In Hyun Jung
Kim M, et al. J Korean Med Sci. 2020 Sep;35(40):e366. https://doi.org/10.3346/jkms.2020.35.e366

1 April 2021 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
HKHun-Tae Kim
Hun-Tae Kim
SJSung-Yun Jung
Sung-Yun Jung
JNJong-Ho Nam
Jong-Ho Nam
JLJung-Hee Lee
Jung-Hee Lee
CLChan-Hee Lee
Chan-Hee Lee
JCJei-Keon Chae
Jei-Keon Chae

4 March 2024 in Clinical Cardiology
Verified
Journal Article
Open access
JKJee‐Heon Kim
Jee‐Heon Kim
YYYoung‐Chae Yoon
Young‐Chae Yoon
YKYoung‐Hoon Kim
Young‐Hoon Kim
JPJong‐Il Park
Jong‐Il Park
KCKang-Un Choi
Kang-Un Choi
UKUng Kim
Ung Kim
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.

1 January 2020 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JLJung-Hee Lee
Jung-Hee Lee
SESang-Yong Eom
Sang-Yong Eom
UKUng Kim
Ung Kim
CLChan-Hee Lee
Chan-Hee Lee
JSJang-Won Son
Jang-Won Son
JPJong Sun Park
Jong Sun Park
Lee JH, et al. Korean Circ J. 2019 Aug;50:e17. https://doi.org/10.4070/kcj.2019.0206

1 January 2017 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JNJong-Ho Nam
Jong-Ho Nam
KPKyu-Hwan Park
Kyu-Hwan Park
JLJung-Hee Lee
Jung-Hee Lee
CLChan-Hee Lee
Chan-Hee Lee
JSJang-Won Son
Jang-Won Son
DSDong-Gu Shin
Dong-Gu Shin
Oxidative stress (OS) plays an important role in the pathophysiology of atrial fibrillation (AF) by amplifying the inflammatory cascade, wherein augmented inflammation facilitates the atrial electrical remodeling process. Few studies have investigated the possible link between systemic inflammation and OS in AF. A total of 220 consecutive patients with AF (117 patients) or healthy controls (103 patients) were enrolled. Among the 117 AF patients, 65 paroxysmal AF (PaAF) and 52 persistent AF (PeAF) patients were included. The level of 8-iso-prostaglandin F2α (8-iso-PGF2α) was measured as a marker of OS burden. We evaluated the correlations between 3 systemic inflammatory markers, high-sensitivity C-reactive protein (hsCRP), neutrophil to lymphocyte ratio (NLR), and red cell distribution width (RDW), and 8-iso-PGF2α. The 8-iso-PGF2α concentration in both PaAF and PeAF patients was higher than that of controls (p<0.001 and p=0.024, respectively). The NLR and RDW of PeAF patients were higher than those of both control and PaAF patients (p=0.041 and p=0.031 for NLR, p=0.057 and p=0.031 for RDW, respectively). There were no correlations between specific inflammatory markers and the 8-iso-PGF2α in AF. The 8-iso-PGF2α level decreased gradually with an increase in AF duration (p=0.008), contrary to the graded increase in hsCRP. Multiple regression analysis indicated that AF duration persisted as a significant determinant of 8-iso-PGF2α (β=-0.249, p=0.044). Systemic inflammatory marker levels were not proportional to the levels of 8-iso-PGF2α, an OS marker, in AF.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HLHee Jeong Lee
Hee Jeong Lee
ICIksung Cho
Iksung Cho
DKDae-Young Kim
Dae-Young Kim
JSJang-Won Son
Jang-Won Son
KCKang-Un Choi
Kang-Un Choi
JNJagat Narula
Jagat Narula
Lee HJ, et al. J Korean Med Sci. 2024 Apr;39(17):e152. https://doi.org/10.3346/jkms.2024.39.e152